CN114574377A - 一株产腺苷蛋氨酸的酿酒酵母工程菌及其应用 - Google Patents
一株产腺苷蛋氨酸的酿酒酵母工程菌及其应用 Download PDFInfo
- Publication number
- CN114574377A CN114574377A CN202210027682.XA CN202210027682A CN114574377A CN 114574377 A CN114574377 A CN 114574377A CN 202210027682 A CN202210027682 A CN 202210027682A CN 114574377 A CN114574377 A CN 114574377A
- Authority
- CN
- China
- Prior art keywords
- saccharomyces cerevisiae
- sam
- producing
- adenosylmethionine
- fermentation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 title claims abstract description 70
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 49
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 title claims abstract description 49
- 241000894006 Bacteria Species 0.000 title claims abstract description 26
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 32
- 238000004519 manufacturing process Methods 0.000 claims abstract description 24
- 238000000855 fermentation Methods 0.000 claims description 39
- 230000004151 fermentation Effects 0.000 claims description 39
- 101100281510 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) met-6 gene Proteins 0.000 claims description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 14
- 239000008103 glucose Substances 0.000 claims description 14
- 108010075604 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Proteins 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 229960001570 ademetionine Drugs 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 239000011593 sulfur Substances 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 108010061618 O-succinylhomoserine (thiol)-lyase Proteins 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 239000001888 Peptone Substances 0.000 claims description 4
- 108010080698 Peptones Proteins 0.000 claims description 4
- 235000019319 peptone Nutrition 0.000 claims description 4
- 102000011848 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Human genes 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000007836 KH2PO4 Substances 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 2
- 229910052564 epsomite Inorganic materials 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 abstract description 9
- 230000002018 overexpression Effects 0.000 abstract description 9
- 239000001963 growth medium Substances 0.000 abstract description 7
- 238000005457 optimization Methods 0.000 abstract description 5
- 230000004048 modification Effects 0.000 abstract description 4
- 238000012986 modification Methods 0.000 abstract description 4
- 230000037353 metabolic pathway Effects 0.000 abstract description 3
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 30
- 229930195722 L-methionine Natural products 0.000 description 30
- 229960004452 methionine Drugs 0.000 description 30
- 239000002609 medium Substances 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 101150090973 STR2 gene Proteins 0.000 description 9
- 238000009825 accumulation Methods 0.000 description 9
- 230000005526 G1 to G0 transition Effects 0.000 description 8
- 239000012634 fragment Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 239000002028 Biomass Substances 0.000 description 3
- 241000560573 Celerinatantimonas yamalensis Species 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 101150021948 SAM2 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 238000010812 external standard method Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 101150002012 met6 gene Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 239000007222 ypd medium Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/38—Nucleosides
- C12P19/40—Nucleosides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y201/00—Transferases transferring one-carbon groups (2.1)
- C12Y201/01—Methyltransferases (2.1.1)
- C12Y201/01013—Methionine synthase (2.1.1.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01006—Methionine adenosyltransferase (2.5.1.6), i.e. adenosylmethionine synthetase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
- C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
- C12Y205/01048—Cystathionine gamma-synthase (2.5.1.48)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Neurosurgery (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
Abstract
本发明公开了一株产腺苷蛋氨酸的酿酒酵母工程菌及其应用,属于基因工程领域。以Saccharomyces cerevisiae CEN.PK2‑1C为底盘细胞,在过表达腺苷蛋氨酸合酶的基础上,通过代谢通路改造,提高胞内L‑Met供给,促进SAM生产,构建一株产SAM的酿酒酵母工程菌,并对其进行培养基优化,进一步提高其SAM生产水平,最终SAM产量达到1465.4mg/L,具有重要的工业应用前景。
Description
技术领域
本发明涉及一种产腺苷蛋氨酸的酿酒酵母工程菌及其应用,具体涉及整合过表达酿酒酵母来源的sam2、met6、str2基因和培养基优化,属于基因工程领域。
背景技术
腺苷蛋氨酸(S-adenosyl-L-methionine,SAM)属于体内生理活性分子,在许多生物甲基化中提供甲基,而且是多胺亚精胺和精胺、金属离子螯合化合物烟胺合成前体,在医疗方面具有重要作用。SAM在生物体中以L-蛋氨酸(L-Met)和ATP为直接前体,由腺苷蛋氨酸合酶催化生成。工业大量生产SAM主要是发酵法,因为发酵法相较于其它生产方法,生产成本低,生产过程简单。
酿酒酵母是理想的底盘细胞,因其具有充满带负电的聚磷酸盐的液泡,能够富集带正电的SAM,是目前用于工业生产的常用宿主。L-Met是SAM合成的重要前体,L-Met在胞内的积累量将直接影响SAM的生产,目前工业生产最常用的手段是在发酵培养基中添加L-Met。但是,发酵培养基中过量的L-Met抑制酵母生长,培养基中L-Met超过1%会明显抑制产量。代谢通路改造的方式来提高胞内L-Met的积累,能减少外源添加L-Met对菌株的影响,具有重大应用前景。
发明内容
本发明要解决的技术问题是通过代谢通路改造,构建高产SAM的酿酒酵母菌株,并对其进行培养基优化,进一步提高其SAM生产水平。
本发明的第一个目的是提供一种高产腺苷蛋氨酸的酿酒酵母工程菌,过表达腺苷蛋氨酸合酶基因sam2。
本发明的另一个目的是提供一种高产腺苷蛋氨酸的酿酒酵母工程菌,同时过表达腺苷蛋氨酸基因sam2和酶蛋氨酸合酶基因met6。
本发明的另一个目的是提供一种高产腺苷蛋氨酸的酿酒酵母工程菌,同时过表达腺苷蛋氨酸合酶基因sam2、蛋氨酸合酶基因met6和胱硫醚-γ-合酶基因str2。
在一种实施例中,sam2、met6、str2基因均来源于酿酒酵母。
本发明的另一个目的是提供一种发酵生产腺苷蛋氨酸的方法,将所述酿酒酵母工程菌接种至发酵培养基中,通过调整碳源和硫源优化发酵过程。
在一种实施方式中,所述发酵培养基中葡萄糖浓度为50-110g/L。
在一种实施方式中,所述发酵培养基中Na2S2O3浓度为0-1g/L。
在一种实施方式中,所述发酵培养基含有:葡萄糖90g/L,蛋白胨10g/L,酵母粉5g/L, KH2PO4 4g/L,K2HPO4 2g/L,MgSO4·7H2O 0.5g/L,Na2S2O3 1g/L,L-Met 1.5g/L。
本发明还要求保护所述酵母工程菌及发酵方法在医疗行业制备肝脏疾病、骨关节炎或神经疾病等药物方面的应用。
有益效果:
本发明首次通过共表达sam2、met6、str2基因,通过提高胞内L-Met的积累,促进SAM 产量提高,所得重组酿酒酵母菌株在发酵24h后L-Met积累量820.0mg/L,SAM产量为1070.8mg/L,比酿酒酵母(Saccharomyces cerevisiae CEN.PK 2-1C)C0提高9.83倍,生产强度达到44.6mg/L/h,比酿酒酵母(Saccharomyces cerevisiae CEN.PK 2-1C)C0显著提高。
本发明通过发酵培养基优化,使上述酿酒酵母(Saccharomyces cerevisiaeCEN.PK 2-1C) 工程菌胞内L-Met的积累量为1155.1mg/L,SAM产量达到1465.4mg/L,生产强度为61.0 mg/L/h,与优化之前相比,分别提高了40.8%,36.8%和36.7%。
附图说明
图1为菌株C0、C1、C2的发酵特性;
图2为菌株C0、C3、C4的发酵特性;
图3为菌株C0、C2、C6的发酵特性;
图4为菌株C7在不同浓度葡萄糖和Na2S2O3条件下的SAM和L-Met产量;
图5为菌株C6、C7发酵过程中的菌浓(A)、SAM和L-Met产量(B)以及葡萄糖消耗情况。
具体实施方式
YPD培养基:蛋白胨20g/L,醇母粉10g/L,葡萄糖20g/L(固体培养基添加20g/L琼脂粉)。
LB培养基:酵母粉5g/L,蛋白胨10g/L,NaCl 10g/L。
HPLC分析腺苷蛋氨酸产量:色谱柱为Hypercil GOLDTM aQ C18(4.6mm×250mm),流动相为:0.01mol·L-1甲酸铵和3%(v/v)的甲醇水溶液,用甲酸调节pH为3.0,流速1.0mL·min-1,检测波长254nm,进样量为10μL。采用外标法,根据不同浓度的SAM标准品所对应峰面积所作标准曲线定量样品SAM的含量。
HPLC分析L-蛋氨酸产量:色谱柱为Hypercil GOLDTM aQ C18(4.6mm×250mm),流动相为:10%(v/v)的甲醇水溶液,流速1.0mL·min-1,检测波长210nm,进样量为10μL。采用外标法,根据不同浓度的L-Met标准品所对应峰面积所作标准曲线定量样品L-Met的含量。
生物量检测:取适量检测点的样品稀释至OD600值为0.2-0.8,于600nm处测取吸光度。
葡萄糖检测:离心后的上清液稀释50倍,使用西尔曼生物传感器测葡萄糖含量。
实施例1构建含腺苷蛋氨酸合酶、蛋氨酸合酶、胱硫醚-γ-合酶的重组质粒
一、重组表达载体的构建
(1)酿酒酵母来源腺苷蛋氨酸合酶基因表达质粒的构建
以sam2F和sam2R为引物,扩增出基因组上的sam2片段,采用BamHI和HindIII双酶切pRS306质粒和扩增片段sam2,采用T4 DNA连接酶16℃过夜连接,获得pRS306-sam2。
(2)酿酒酵母来源蛋氨酸合酶基因表达质粒的构建
以met6F和met6R为引物扩增得到met6片段,采用SalI酶切线性化pRS305质粒,后采用诺唯赞C112单片段同源重组连接试剂盒获得pRS305-met6。
(3)酿酒酵母来源胱硫醚-γ-合酶基因表达质粒的构建
以str2F和str2R为引物扩增得到str2片段,采用SalI酶切线性化pRS305质粒,后采用诺唯赞C112单片段同源重组连接试剂盒获得pRS305-str2。以Tstr2CF和Tstr2CR为引物扩增得到str2表达框,以引物305F和305R反向PCR线性化pRS305-met6,后采用诺唯赞C112 单片段同源重组连接试剂盒获得pRS305-met6str2。
(4)引物设计如表1,序列自上而下分别命名为SEQIDNO.1-16。
表1质粒构建所用引物
(5)PCR反应体系为:引物各1μL,模板1μL,2×PrimeStar 25μL、ddH2O 22μL。反应条件为预变性:95℃,3min;变性:95℃,30s;退火:视引物Tm值而定,30s;延伸: 72℃,视基因长度而定,34个循环,72℃,5min。PCR反应结束后,将产物进行琼脂糖凝胶电泳分析,利用胶回收试剂盒进行产物回收纯化。
(6)酶切体系及条件如表2所示,反应结束将产物进行电泳验证回收。
表2酶切反应体系与反应条件
(7)大肠转化条件:将同源重组产物转化至E.coli JM109感受态细胞中,涂布带有Amp 抗生素的LB固体培养基,于恒温箱倒置培养8-12h长出转化子。挑取转化子,采用yz1和yz2引物进行菌落PCR验证。将菌落PCR验证阳性的转化子挑取至含Amp抗性的LB培养基中培养8-12h,提取质粒后进一步进行测序验证。
实施例2在酿酒酵母中过表达sam2
将pRS306、pRS306-sam2质粒线性化后转化至酿酒酵母(Saccharomycescerevisiae CEN.PK 2-1C)C0中,将其命名为C1、C2。对C0、C1、C2在发酵培养基中进行摇瓶发酵,结果如图1所示。从菌株生长来看,C1、C2在24h进入稳定期,C0在36h进入稳定期;同时,葡萄糖也随着进入稳定期消耗殆尽。工程菌C1、C2的最高生物量是C0的2.71、2.53倍,可能的原因是质粒的整合弥补了C0尿嘧啶缺陷的影响。工程菌C2在发酵24h后SAM产量达到623.9mg/L,相较于C0的产量108.9mg/L提高了5.72倍,此时,C2工程菌株SAM的生产强度达到25.9mg/L/h。
实施例3在酿酒酵母中单独过表达met6及同时过表达sam2 met6
(1)在酿酒酵母中单独过表达met6
本文将pRS305、pRS305-met6质粒线性化后转化至C0中,将其命名为C3、C4。对C3、C4在发酵培养基中进行摇瓶发酵,结果如图2所示。从菌株生长来看,C3、C4在36h进入稳定期。工程菌C3、C4的生物量与C0相差不大,met6基因的过表达对菌株生长没有造成负担。工程菌C4在发酵24h后SAM产量为102.9mg/L,相较于C0并无明显变化。C4的 L-Met胞内含量明显高于C0,提高22.7%。
(2)在酿酒酵母中同时过表达sam2和met6
将pRS305、pRS305-met6质粒线性化后转化至C2中,将其命名为C5、C6。在发酵培养基中对C5、C6进行摇瓶发酵,结果如图3所示。C5、C6在24h进入稳定期,同时,葡萄也随着进入稳定期消耗殆尽,且sam2和met6基因的共表达并未对菌株造成代谢压力,菌株生长状态未见明显影响。工程菌C6在发酵24h后SAM产量为837.2mg/L,与单独表达sam2 相比提高了34.1%,生产强度为34.8mg/L/h,与单独表达sam2相比提高了34.3%。同时,比较了C2和C6的胞内L-Met积累量,从发酵时间来看,L-Met的最高产量均出现在SAM最高产量之前,随着SAM产量的提高胞内浓度下降,随后维持在一定水平;C6的L-Met的最高浓度528.5mg/L明显高于C2,前者是后者的1.33倍,说明表达met6确实有利于提高胞内 L-Met的浓度,从而提高SAM产量。
实施例4在酿酒酵母中进一步过表达str2
将pRS305-met6str2质粒线性化后转化至C2中,将其命名为C7。对C7在发酵培养基中进行摇瓶发酵,结果如图4所示。从菌株生长来看,C7在24h达到稳定期,葡萄糖随着进入稳定期消耗殆尽,且进一步过表达str2基因对菌株生长未造成明显影响。工程菌C7在发酵24h后SAM产量为1070.8mg/L,生产强度达到44.6mg/L/h,与C6相比,SAM产量提高27.0%,生产强度提高28.1%;与C2相比SAM产量提高了71.6%,生产强度提高72.2%,str2 基因对SAM生产的影响显著。同时,如图4所示,我们发现C7相较于C6,胞内L-Met的积累量明显提高了55.0%,证实了str2在L-Met合成的重要作用,能够大幅提高胞内L-Met 的供给,为SAM的合成提供更多的前体L-Met。
实施例5对酿酒酵母工程菌产腺苷蛋氨酸培养基条件优化
对实施例4中SAM生产水平提高最多的工程菌C7进行进一步发酵条件优化。
(1)碳源对工程菌C7的影响
对葡萄糖的浓度进行了提高,如图5所示,随着葡萄糖浓度的提高,前体L-Met的浓度在不断提高,SAM的产量也随之提高。当葡萄糖浓度90g/L时,发酵24h,SAM产量达到1302.0mg/L,较葡萄糖浓度50g/L时提高了21.5%,此时,L-Met积累量由820.0mg/L提升至1105.1mg/L,说明碳源是SAM合成的限制因素,在对SAM合成途径进行代谢改造之后,应考虑菌株生长对碳源需求的变化。
(2)硫源对工程菌C7的影响
进行了Na2S2O3的添加实验,如图5所示,在Na2S2O3的浓度从0g/L提高到1g/L使, L-Met积累量由1102.6mg/L增加到1155.1mg/L,变化不大,SAM产量达到1465.4mg/L,较不添加时提高了12.5%,生产强度为61.0mg/L/h,说明硫源是影响SAM合成的因素,在合成此类含硫氨基酸时,应充分考虑菌株生长对硫源的需求。当Na2S2O3的添加量超过1g/L时,会使菌株的生长缓慢,发酵周期变长,使生产效率降低。
虽然本发明已以较佳实施例公开如上,但其并非用以限定本发明,任何熟悉此技术的人,在不脱离本发明的精神和范围内,都可做各种的改动与修饰,因此本发明的保护范围应该以权利要求书所界定的为准。
SEQUENCE LISTING
<110> 江南大学
<120> 一株产腺苷蛋氨酸的酿酒酵母工程菌及其应用
<130> BAA220042A
<160> 16
<170> PatentIn version 3.3
<210> 1
<211> 30
<212> DNA
<213> 人工序列
<400> 1
cgcggatcca tgtccaagag caaaactttc 30
<210> 2
<211> 35
<212> DNA
<213> 人工序列
<400> 2
gggggcccaa gcttttaaaa ttccaatttc tttgg 35
<210> 3
<211> 51
<212> DNA
<213> 人工序列
<400> 3
ctgcaggaat tcgatatcaa gcttatggtt caatctgctg tcttagggtt c 51
<210> 4
<211> 58
<212> DNA
<213> 人工序列
<400> 4
gaggtcgacg gtatcgataa gcttttaatt cttgtattgt tcacggaagt acttggcg 58
<210> 5
<211> 74
<212> DNA
<213> 人工序列
<400> 5
cgatatcaag cttatcgata ccgtcgacat gatatctaga accattggtg aatctattccgcccaacaca aaac 74
<210> 6
<211> 58
<212> DNA
<213> 人工序列
<400> 6
actaattaca tgactcgagg tcgacttatt cccctaaagc tttctcaatg gcacgctg 58
<210> 7
<211> 68
<212> DNA
<213> 人工序列
<400> 7
gctgcattaa tgaatcggcc aacgcgcggg aatgtttcta ctcctttttt actcttccagattttctc 68
<210> 8
<211> 61
<212> DNA
<213> 人工序列
<400> 8
aggaagcgga agagcgccca atacgcaaac cgcctctcgc aaattaaagc cttcgagcgt c 61
<210> 9
<211> 30
<212> DNA
<213> 人工序列
<400> 9
gagaggcggt ttgcgtattg ggcgctcttc 30
<210> 10
<211> 26
<212> DNA
<213> 人工序列
<400> 10
cccgcgcgtt ggccgattca ttaatg 26
<210> 11
<211> 25
<212> DNA
<213> 人工序列
<400> 11
aggccttttg atgttagcag aattg 25
<210> 12
<211> 26
<212> DNA
<213> 人工序列
<400> 12
ctaggttcct ttgttacttc ttctgc 26
<210> 13
<211> 26
<212> DNA
<213> 人工序列
<400> 13
tagggccatg aaagcggcca ttcttg 26
<210> 14
<211> 30
<212> DNA
<213> 人工序列
<400> 14
caacatgagc caccattgcc tatttggtcc 30
<210> 15
<211> 25
<212> DNA
<213> 人工序列
<400> 15
gcaattaacc ctcactaaag ggaac 25
<210> 16
<211> 23
<212> DNA
<213> 人工序列
<400> 16
caaggcgatt aagttgggta acg 23
Claims (10)
1.一株产腺苷蛋氨酸的酿酒酵母工程菌,其特征在于过表达腺苷蛋氨酸合酶基因sam2。
2.一株产腺苷蛋氨酸的酿酒酵母工程菌,其特征在于同时过表达腺苷蛋氨酸合酶基因sam2和酶蛋氨酸合酶基因met6。
3.一株产腺苷蛋氨酸的酿酒酵母工程菌,其特征在于同时过表达腺苷蛋氨酸合酶基因sam2、蛋氨酸合酶基因met6和胱硫醚-γ-合酶基因str2。
4.权利要求1-3任一所述的酿酒酵母工程菌,其特征在于所述腺苷蛋氨酸合酶基因sam2、蛋氨酸合酶基因met6和胱硫醚-γ-合酶基因str2均来源于酿酒酵母。
5.应用权利要求4所述酿酒酵母工程菌发酵生产腺苷蛋氨酸的方法,其特征在于将所述酿酒酵母工程菌接种至发酵培养基中,通过调整碳源和硫源优化发酵过程。
6.权利要求5所述的方法,其特征在于所述发酵培养基中葡萄糖的浓度为50-110g/L。
7.权利要求5所述的方法,其特征在于所述发酵培养基中Na2S2O3的浓度为0-1g/L。
8.权利要求5-7任一所述的方法,其特征在于所述发酵培养基含有:葡萄糖90g/L,蛋白胨10g/L,酵母粉5g/L,KH2PO4 4g/L,K2HPO4 2g/L,MgSO4·7H2O 0.5g/L,Na2S2O3 1g/L,L-Met1.5g/L。
9.权利要求1-3任一所述酿酒酵母工程菌应用于制备肝脏疾病、骨关节炎相关药物。
10.权利要求1-3任一所述酿酒酵母工程菌应用于制备神经疾病类药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210027682.XA CN114574377B (zh) | 2022-01-11 | 2022-01-11 | 一株产腺苷蛋氨酸的酿酒酵母工程菌及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210027682.XA CN114574377B (zh) | 2022-01-11 | 2022-01-11 | 一株产腺苷蛋氨酸的酿酒酵母工程菌及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114574377A true CN114574377A (zh) | 2022-06-03 |
CN114574377B CN114574377B (zh) | 2023-10-27 |
Family
ID=81772803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210027682.XA Active CN114574377B (zh) | 2022-01-11 | 2022-01-11 | 一株产腺苷蛋氨酸的酿酒酵母工程菌及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114574377B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103087934A (zh) * | 2012-01-16 | 2013-05-08 | 浙江工商大学 | 高产s-腺苷蛋氨酸的巴斯德毕赤酵母菌株的构建方法 |
CN103993055A (zh) * | 2014-04-22 | 2014-08-20 | 浙江工业大学 | 一种生物合成腺苷蛋氨酸的方法 |
CN112266923A (zh) * | 2020-10-30 | 2021-01-26 | 江南大学 | 一种表达腺苷蛋氨酸合酶的枯草芽孢杆菌及应用 |
CN112322512A (zh) * | 2019-08-05 | 2021-02-05 | 浙江大学 | 基于crispr技术改造酿酒酵母利用dl-蛋氨酸合成s-腺苷蛋氨酸的方法 |
-
2022
- 2022-01-11 CN CN202210027682.XA patent/CN114574377B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103087934A (zh) * | 2012-01-16 | 2013-05-08 | 浙江工商大学 | 高产s-腺苷蛋氨酸的巴斯德毕赤酵母菌株的构建方法 |
CN103993055A (zh) * | 2014-04-22 | 2014-08-20 | 浙江工业大学 | 一种生物合成腺苷蛋氨酸的方法 |
CN112322512A (zh) * | 2019-08-05 | 2021-02-05 | 浙江大学 | 基于crispr技术改造酿酒酵母利用dl-蛋氨酸合成s-腺苷蛋氨酸的方法 |
CN112266923A (zh) * | 2020-10-30 | 2021-01-26 | 江南大学 | 一种表达腺苷蛋氨酸合酶的枯草芽孢杆菌及应用 |
Non-Patent Citations (2)
Title |
---|
HAILONG CHEN ET AL: "Improving methionine and ATP availability by MET6 and SAM2 co-expression combined with sodium citrate feeding enhanced SAM accumulation in Saccharomyces cerevisiae", WORLD J MICROBIOL BIOTECHNOL, vol. 32, no. 56, pages 1 - 10 * |
毛职医等: "大肠杆菌表达腺苷蛋氨酸合酶及产酶条件优化", 食品与发酵工业, vol. 46, no. 10, pages 8 - 13 * |
Also Published As
Publication number | Publication date |
---|---|
CN114574377B (zh) | 2023-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102015829B1 (ko) | 온라인 산소 소비율과 전도율의 통합 제어를 기반으로 한 코엔자임 q10 발효 생산 공정 | |
EP2975114A1 (en) | Strain having enhanced l-valine productivity and l-valine production method using the same | |
CN113774075B (zh) | 一株大肠杆菌基因工程菌及其发酵生产l-茶氨酸的方法 | |
JP2001525682A (ja) | 改良された性質を有する形質転換微生物 | |
CN108456652B (zh) | 一种鞘氨醇单胞菌基因工程菌及其构建方法与应用 | |
JP4494716B2 (ja) | 菌類による異種たんぱく質の生産方法 | |
CN116121161A (zh) | 一种生产麦角硫因的基因工程菌及其构建方法与应用 | |
CN112779173B (zh) | 一种高产谷胱甘肽毕赤酵母菌株g3-sf及其应用 | |
CN107287197B (zh) | 组氨酸衰减子突变体和解决反馈阻遏的组氨酸操纵子以及它们的应用 | |
CN113073074A (zh) | 一种高效合成核黄素的基因工程菌及其应用 | |
JP7072809B2 (ja) | 組換え微生物、その製造方法及び補酵素q10の生産における使用 | |
CN114574377B (zh) | 一株产腺苷蛋氨酸的酿酒酵母工程菌及其应用 | |
CN115125224A (zh) | 一种可规模化生产具有活性的dna聚合酶的方法 | |
CN110616161B (zh) | 一种利用Y家族聚合酶Rev1调节酿酒酵母氧胁迫的方法 | |
CN112646738A (zh) | 一种高产谷胱甘肽毕赤酵母菌株g3-sa及其应用 | |
CN115896211A (zh) | 一种发酵生产胞磷胆碱的基因工程菌及应用 | |
CN108424859B (zh) | 生产胞磷胆碱的基因工程菌的构建与应用 | |
CN116286939B (zh) | 一种提高酿酒酵母核酸产量的方法及应用 | |
CN114717250B (zh) | 一种基于辅因子代谢工程策略改造蛹虫草菌提高虫草素产量的方法及应用 | |
CN114410494B (zh) | 一种生产迷迭香酸的酿酒酵母工程菌及其构建方法和应用 | |
CN116024278B (zh) | 一种发酵法制备d-泛酸的方法 | |
CN117946954B (zh) | 一种亮氨酸生产菌株及其构建方法与应用 | |
CN116970662B (zh) | 一种利用工程菌制备麦角硫因的方法 | |
CN116179380A (zh) | 一种高产丙酮酸的解脂耶氏酵母工程菌wsmhp、构建方法及应用 | |
JP2833037B2 (ja) | グルタチオン高含有酵母の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |